Seiji Miyahara
Director/Board Member bij EpiBiologics, Inc.
Profiel
Dr. Miyahara is a Senior Investment Director at Taiho Ventures.
He has over 18 years of experience in the life sciences industry spanning R&D, company creation and venture capital investments across a broad range of modalities.
Currently he serves as a member of the board of directors or board observer for multiple Taiho portfolio companies.
Prior to joining Taiho Ventures in 2016, he worked at Taiho Pharmaceutical for 12 years mainly in oncology field, where he played a critical role in advancing multiple programs into the clinical stage.
He received his PhD in life science from Hokkaido University, Japan.
Actieve functies van Seiji Miyahara
| Bedrijven | Functie | Begin |
|---|---|---|
Taiho Ventures LLC
 Taiho Ventures LLC Investment ManagersFinance Taiho Ventures LLC (Taiho Ventures) is a venture and private equity subsidiary of Taiho Pharmaceutical Co Ltd founded in 2016. The firm is headquartered in Menlo Park, California. | Private Equity Investor | 01-07-2016 |
Hc Bioscience, Inc.
 Hc Bioscience, Inc. Pharmaceuticals: MajorHealth Technology hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then. | Director/Board Member | - |
EpiBiologics, Inc.
 EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Director/Board Member | 20-07-2023 |
Opleiding van Seiji Miyahara
| Hokkaido University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Taiho Ventures LLC
Taiho Ventures LLC Investment ManagersFinance Taiho Ventures LLC (Taiho Ventures) is a venture and private equity subsidiary of Taiho Pharmaceutical Co Ltd founded in 2016. The firm is headquartered in Menlo Park, California. | Finance |
Hc Bioscience, Inc.
Hc Bioscience, Inc. Pharmaceuticals: MajorHealth Technology hC Bioscience, Inc. is a biotech company based in Cambridge, MA and has subsidiaries in the United States. A single trna therapy has the potential to treat many diseases, regardless of the gene or location of the mutation. hC Bioscience is dedicated to improving the lives of patients by developing first-in-class trna-based therapeutics that target protein dysfunction. The company's innovative approach to precision protein editing has the potential to treat genetically defined conditions that account for 10-15% of all human diseases. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). The company was founded in 2021 by Leslie J. Williams, who has been the CEO since then. | Health Technology |
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Commercial Services |
